Tykerb: a go

After announcement of the positive Ph3 it seemed like just a matter of time, and that time has come. Tykerb gets FDA approval in combination with Xeloda for treatement of advanced metatatic breast cancer where the cancer overexpresses Her2 as a second line therapy. And yes that is a mouthful… a 1.25g/d mouthful, worth eventually an estimated 1b/y.